BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/30/2019 2:18:31 AM | Browse: 925 | Download: 1376
 |
Received |
|
2019-03-19 01:34 |
|
Peer-Review Started |
|
2019-03-19 14:59 |
|
To Make the First Decision |
|
2019-08-06 06:37 |
|
Return for Revision |
|
2019-08-08 08:04 |
|
Revised |
|
2019-08-14 00:40 |
|
Second Decision |
|
2019-08-21 08:44 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-08-21 23:18 |
|
Articles in Press |
|
2019-08-21 23:18 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-08-28 13:42 |
|
Typeset the Manuscript |
|
2019-09-04 01:18 |
|
Publish the Manuscript Online |
|
2019-09-30 02:18 |
| ISSN |
2218-4333 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Editorial |
| Article Title |
Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jianbiao Zhou and Wee-Joo Chng |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jianbiao Zhou, MD, PhD, Senior Scientist, Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, 28 Medical Drive, Singapore 117456, Singapore. csizjb@nus.edu.sg |
| Key Words |
Multiple myeloma; Proteasome inhibitor; Bortezomib; Proteasome β5-subunit; Drug resistance; Clonal evolution |
| Core Tip |
Multiple myeloma (MM) is the second common hematologic malignancy. An array of new treatments has been approved over the last decade. Hence, the survival of MM patients has improved steadily. Among these new drugs, the first-in-class proteasome inhibitor bortezomib has been revolutionary for targeted therapy. Now bortezomib is the backbone for treating MM. However, emerging drug resistance poses a major challenge for clinicians to use proteasome inhibitors. In this editorial, we discuss proteasome β5-subunit mutations as a novel resistant mechanism to bortezomib and its implication in tracking clonal evolution and suggest potential strategies to overcome drug resistance. |
| Publish Date |
2019-09-30 02:18 |
| Citation |
Zhou J, Chng WJ. Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma. World J Clin Oncol 2019; 10(9): 303-306 |
| URL |
https://www.wjgnet.com/2218-4333/full/v10/i9/303.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v10.i9.303 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
